Fig. 34.Development and cellular mechanism ofTafamidis(50). (A) Structure and key profiles of biological activity ofTafamidis(50). (B) The MOA ofTafamidis(50) and simplified illustration of TTR as a FIC target in ATTR. Selinexor(52) was developed by Karyopharm and granted accelerated approval...
Pfizer’s tafamidis was also found to have minimised the decline in quality of life aspects as measured using the Kansas City Cardiomyopathy Questionnaire at month 30. “We believe the ATTR-ACT study findings bring us a significant step closer to our goal of providing an urgently needed therapy ...
Overall, in a real-world setting, tafamidis was associated with a decline in NT-proBNP and well-tolerated in our patients.doi:10.1161/circoutcomes.15.suppl_1.21Ugochukwu EgolumChristine SykaloMoaz AhmadDrew CatesHua LingCirculation-Cardiovascular Quality and Outcomes...